Welcome to our dedicated page for RxSight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RxSight, Inc. filings document the public-company record for a Nasdaq-listed ophthalmic medical device issuer centered on the RxSight Light Adjustable Lens system. Form 8-K reports furnish operating results, sales guidance, Light Adjustable Lens and Light Delivery Device commercial metrics, preliminary results and other material updates tied to financial condition.
The company’s proxy and governance filings cover annual meeting matters, board and committee composition, executive compensation, equity awards and stockholder voting procedures. Other current reports address officer appointments, transition agreements, compensatory arrangements and the registered common stock structure for RXST.
RxSight, Inc. (RXST) reported that Chief Business Development Officer Eric Weinberg exercised stock options for 35,168 shares of common stock on September 15, 2026 at an exercise price of $4.34 per share, increasing his directly held common stock to 235,516 shares.
He also is reported as having indirect ownership of 299,978 shares of common stock through the EJW Living Trust, where he serves as trustee, and 925 shares held by his spouse. The options exercised were fully vested and exercisable, and no Rule 10b5-1 trading plan is reported for these transactions.
RxSight, Inc. (RXST) reported that Chief Financial Officer Mark Wilterding participated in an option exchange on September 5, 2026. An existing stock option for 258,770 shares with a $10.09 exercise price was returned to the issuer and replaced on a 1:1 basis with a new option for 258,770 shares at a $6.375 exercise price. The new option vests in equal monthly installments over 24 months starting February 28, 2027, contingent on continued service.
RxSight, Inc. reported an option exchange for Chief Business Development Officer Eric Weinberg on September 5, 2026. Several outstanding stock options were returned to the company, including grants for 87,437, 95,000, 92,200, 50,000, and 125,000 shares with exercise prices ranging from $14.95 to $56.07 per share. In connection with the issuer’s option exchange program, these were replaced with new options for 65,742, 82,608, 59,483, 32,258, and 93,984 shares at a post‑exchange exercise price of $6.375 per share, subject to time‑based vesting conditions through 2027. No Rule 10b5‑1 trading plan is reported, and all positions are held directly.
RxSight, Inc. reported that Chief Medical Officer Ronald M. Kurtz, MD adjusted his equity awards on September 5, 2026 in connection with an option exchange program. He returned four outstanding stock option grants to the company and received four replacement options with a lower exercise price of $6.375 per share, each with specified vesting schedules tied to continued service.
RxSight, Inc. (RXST) reported that Chief Operating Officer Ilya Goldshleger participated in an employee option exchange program on September 5, 2026. Several existing stock options with higher exercise prices, including options exercisable at $16.00, $14.95, $28.21, $46.24, and $56.07 per share, were disposed of to the issuer and replaced on specified exchange ratios with new options.
The new stock options carry a post-exchange exercise price of $6.375 per share and various vesting schedules tied to continued service under the 2021 Equity Incentive Plan. Some new grants vest monthly over 48 months from vesting commencement dates in 2023–2025, while others vest in 2027 on a 25%/75% schedule with additional monthly vesting components.
RxSight, Inc. (RXST) reports the final results of its employee option exchange offer. The offer expired at 9:00 p.m. Pacific Time on September 4, 2026, with 205 eligible employees tendering options to purchase an aggregate of 3,761,461 shares of common stock, representing 91.9% of the shares underlying eligible options held by eligible employees.
On September 5, 2026, RxSight granted options to purchase 1,643,324 shares of common stock to its named executive officers and restricted stock units covering 760,738 shares of common stock to non-executive employees, in each case in exchange for the cancelled options and pursuant to the company’s 2021 Equity Incentive Plan.
RxSight, Inc. (RXST) reports that officer Ronald M. Kurtz has filed a notice of proposed sale under Rule 144 for up to 5,100 shares of RxSight common stock through E-Trade Financial Corporation. The filing lists an aggregate market value of $35,496 and 41,593,256 shares outstanding of this class.
The securities relate to restricted stock units acquired on August 31, 2026, and the notice states that the shares are to be sold to cover withholding taxes upon vesting of these awards. The planned sale date is listed as September 2, 2026 on the NASDAQ market.
RxSight, Inc. (RXST) received a Rule 144 notice indicating that officer Mark Wilterding plans to sell common stock through broker E-Trade Financial Corporation. The notice covers a proposed sale of 7,765 shares of common stock on NASDAQ, with an aggregate market value of $54,044.40. The shares relate to 20,441 shares acquired from restricted stock units vesting on August 31, 2026, and the remarks state that the sale is intended to cover withholding taxes upon vesting. RxSight reports 41,593,256 common shares outstanding as of September 2, 2026.
RxSight, Inc. (RXST) received a Rule 144 notice from officer Ilya Goldshleger covering a planned sale of company common stock. The filing reports that 5,370 shares underlying restricted stock units are to be sold on August 31, 2026. The remarks state the sale is intended to cover withholding taxes upon vesting of these restricted stock unit awards.
RxSight, Inc. (RXST) received a Rule 144 notice indicating that officer Eric Weinberg plans to sell common stock. The notice covers the potential sale of 5,370 shares of common stock, related to the vesting of restricted stock unit awards. The filer states that the shares are to be sold to cover withholding taxes upon vesting.